Physician profile
Majd Kobitary
NPI 1649235748
$14,313.24
in general payments reported to CMS, 2019-2025
12 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,165 · 2020: $47.62 · 2021: $18.86 · 2023: $6,099 · 2024: $6,168 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,500 · Travel and Lodging: $5,003 · Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,500.00 |
| Travel and Lodging | $5,003.30 |
| Food and Beverage | $578.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $11,208.82 | 2023-2025 | Da Vinci Surgical System, Ion |
| Medical Device Business Services, INC. | $1,501.71 | 2024-2025 | Monarch |
| Pulmonx Corporation | $1,123.58 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $123.27 | 2019-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $84.40 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Pinnacle Biologics, INC | $70.12 | 2023-2024 | Photofrin |
| Glaxosmithkline, LLC. | $58.35 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $48.98 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $28.02 | 2019-2020 | |
| Olympus Corporation of The Americas | $25.76 | 2019 | |
| Insmed, INC. | $21.37 | 2024 | Arikayce |
| United Therapeutics Corporation | $18.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majd Kobitary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.